Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension

Press Release Nicox Announces NCX 470 NDA Submission in China by Partner OcumensionOcumension has submitted the New Drug Application (NDA) to the Chinese National Medical Products Administration (NMPA) for NCX 470 to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension Same data package as for the recent submission in the U.S.Ocumension already has an ophthalmology sales force throughout ChinaMultiple NCX 470 clinical, approval and launch milestone events expected over the next 12 to 18 monthsAugust 10, 2026 - release at 7:30 am CET CONFIDENTIAL DRAFT